UTHR News and Press, United Therapeutics Corporation From 08/03/23

2023-08-03 17:41:54 ET Summary United Therapeutics Corporation (NASDAQ: UTHR) reported strong quarterly results, adding strength to its economic characteristics. The company's financial performance and cash flows indicate the potential for sustained high returns on operating capit...

2023-08-02 13:11:05 ET United Therapeutics Corporation (UTHR) Q2 2023 Earnings Conference Call August 02, 2023 09:00 AM ET Company Participants Dewey Steadman - Head-Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowit...

2023-08-02 06:02:29 ET United Therapeutics press release ( NASDAQ: UTHR ): Q2 GAAP EPS of $5.24 beats by $0.75 . Revenue of $596.5M (+27.8% Y/Y) beats by $72.33M . Rothblatt, Ph.D., Chairperson and CEO commented, “We expect this growth trajectory to cont...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2023. Total revenues in the second quarter of 2023 grew 28% year-over-year to $596.5 million, compared to $466.9 million in the second quarter of...

2023-08-01 13:28:57 ET United Therapeutics ( NASDAQ: UTHR ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is $4.78 (vs. $2.41 last year) and the consensus Revenue Estimate is $524.17M (+12.3% Y/Y). ...

2023-07-26 13:23:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotechnology industry is simply amazing, always advancing and bringing new drugs to fight complicated and serious diseases. If you are thinking about investing in this sector, it is cruc...

United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its second quarter 2023 financial results before the market opens on Wednesday, August 2, 2023. United Therapeutics will host a public webcast Wednesday, August 2, 2023, at 9:00 a.m. Eastern Time. The web...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the United States Court of Appeals for the Federal Circuit affirmed the district court decision in the patent litigation United Therapeutics brought against Liquidia Technologies, Inc. The Fede...

2023-06-23 13:40:23 ET Summary Liquidia and MannKind are competing to secure the most significant revenue stream for their respective PAH drugs, both containing the active ingredient Treprostinil. Liquidia's stock has increased by 96% in the past year, while MannKind's stock has r...

2023-06-19 05:16:46 ET Summary Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF. 10 healthcare stocks cheaper than their peers in Ju...